Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Trutag Technologies","sponsor":"Spinnaker Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TruTag Technologies and Spinnaker Biosciences Partner on a New Targeted, Controlled Release Therapy for Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Trutag Technologies

    Menu

    Trutag Technologies

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    EXCIPIENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Trutag Technologies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TruTag Technologies and Spinnaker Biosciences Partner on a New Targeted, Controlled Release Therapy for Age-Related Macular Degeneration

              Details:

              Under the agreement, TruTag will supply its advanced nano-porous silica particles to support commercialization of Spinnaker's new therapy, a combination product that involves the loading of the biosimilar Ranibizumab into pSi particles, for age-related macular degeneration.

              Lead Product(s): Silicon Oxide Loaded Ranibizumab

              Therapeutic Area: Ophthalmology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Spinnaker Biosciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership December 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY